93 results about "Trophoblast" patented technology

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of circ0005704 and related biological elements thereof in diagnosis and treatment of recurrent spontaneous abortion with unknown reasons. Researches find that differential expression and autophagy level of ULK1 in trophoblast cells of URSA patients are increased. High-throughput transcriptome sequencing is combined with bioinformatics analysis, and it is found that miR-26a-5p is down-regulated in URSA patients, is responsible for up-regulation of ULK1 and promotes autophagy of trophoblast cells, so that occurrence of URSA is increased. Through a high-throughput transcriptional set screening strategy and dual luciferase reporter gene analysis, it is found that circ0005704 enhances the expression of ULK1 through miR-26a-5p. In a word, the research of the invention shows that the circ0005704 / miR-26a-5p / ULK1 signal axis participates in the pathogenesis of URSA by adjusting the migration of the trophoblast cells, and a new target and scientific evidence are provided for the clinical treatment of URSA.

The invention relates to a recurrent abortion early-warning method based on maternal and fetal immune interaction characteristics, which comprises the following steps: by taking decidua immune cells and trophoblasts as a unit, defining the regulation intensity of a key path of a path in an immune receptivity state; evaluating the coordination degree of signals among different cells by utilizing an information theory method; introducing a maternal and fetal immune receptivity steady-state index UISI; through continuous time sampling analysis, an immune signal offset track is identified; establishing an interactive imbalance index (IEI), and quantifying the imbalance intensity; designing a disturbance and response test; fitting the response trend of the IEI change to the disturbance into a system response curve IRC, and quantifying the recovery capability of the immune system; the IRC and individual clinical features are fused, and a dynamic risk thermodynamic relation is established; intervention window weight factors are constructed, wherein the intervention window weight factors comprise the fluctuation amplitude, the recovery period and the UISI critical value proximity; outputting a dynamic intervention suggestion map, and prompting a doctor to observe a period and a drug intervention starting point; the early warning capability is strong, and the limitation of traditional passive diagnosis is broken through.

The invention relates to a method for inducing mouse trophoblast stem cells in vitro. According to the method, mouse embryonic stem cells are used as starting cells, Sorcs3 gene knockout mouse embryonic stem cells are obtained through a gene editing technology, and in-vitro induced trophoblast stem cells (iTSCs) are efficiently and rapidly obtained by means of a flow cytometry sorting technology and in combination with specific antibody sorting. According to the invention, the Sorcs3 gene is knocked out from the embryonic stem cell, so that the capability of the embryonic stem cell to differentiate to the trophoblast lineage can be obviously enhanced; an important research platform is provided for deeply researching a lineage intertransformation mechanism of cell masses (ICM) and trophoblast (TE) in the blastocysts, and the method has important significance for researching lineage limitation of early embryonic development of mammals and the like.

Provided herein are methods and kits for identifying a pregnancy-associated risk or condition in a subject. In embodiments, the methods include detecting levels of at least one biomarker in a substantially cell-free cervical fluid sample obtained from the subject. In embodiments, the methods include detecting levels of biomarkers in a cervical fluid sample including extravillous trophoblasts (EVT) obtained from the subject.

The present application belongs to the field of cell therapy and immunotherapy, and provides a genetically engineered human trophoblast, a preparation method and application thereof. The human trophoblast takes K562 cells as starting cells, and stably expresses membrane-bound interleukin 21, CD137 ligand and Delta-like ligand 1 after genetic engineering. The constructed K562 three-factor trophoblast can significantly improve the expansion efficiency, activation state and functional stability of NK cells and γδT cells. The synergistic mechanism includes enhancing the proliferation, cytotoxicity and stemness maintenance of NK cells and γδT cells through STAT3, NF-κB and Notch signaling pathways, respectively. The human trophoblast has the advantages of good expression stability, significant functional enhancement, and high activity after freezing and recovery.

The invention belongs to the technical field of biology, and particularly relates to application of baicalin to preparation of a medicine for treating preeclampsia by inhibiting trophoblast ferroptosis induced by NETs. The baicalin inhibits downstream signal transduction by specifically interfering a key activation step of PKC [beta] 2 and a membrane translocation process coupled with a second signal, and finally plays a role in inhibiting ferroptosis of trophoblasts. The discovery provides a brand new perspective for understanding the molecular action mechanism of the medicine. According to the application, baicalin influences ferroptosis induced by NETs in trophoblast cells by inhibiting membrane translocation and activation of PKC beta2, so that the biological function of baicalin is exerted. The discovery of the mechanism further deepens the important significance of people on NETs and baicalin in disease induction and treatment, and a thought is provided for research and development of a new treatment scheme for preeclampsia.

The invention relates to a preparation method of a placenta trophoblast-derived transporter and application of the placenta trophoblast-derived transporter in a medicine for treating spontaneous abortion, which comprises the following steps of: taking out a placenta of a suckling mouse, cutting the placenta into fine tissue blocks, resuspending by using digestive juice, digesting in a water bath kettle at 37 DEG C for 20 minutes, and then stopping digestion by using 1640 culture containing high-temperature heat-inactivated fetal calf serum; diluting and neutralizing collagenase digestive juice according to 5 times of volume; and centrifuging the collagenase digestive juice for multiple times to obtain a precipitate, namely the exosome. And carrying out density gradient centrifugation on the coarse migration body by using Optiprep as a density medium, washing, precipitating and centrifuging by using PBS on an ultra-high-speed centrifuge by using a horizontal rotor to obtain the placental trophoblast source migration body. The invention finds that the generation of the placental trophoblast cell source migration body is related to the physiological process of pregnancy for the first time, and the placental trophoblast cell source migration body can enter the circulatory system and reach the placenta through in-vitro supplementation.

The invention is suitable for the technical field of biology, and provides an L-NAME induced trophoblast organ injury model and a construction method and application thereof, and the construction method of the trophoblast organ injury model comprises the following steps: constructing a trophoblast organ by using human villus tissue; the method comprises the following steps: carrying out culture and passage treatment on a trophoblast organ, and then adding L-NAME with the final concentration of 15-60mM to carry out induced injury, so as to obtain the trophoblast organ injury model. The basic model used in the invention is a trophoblast-like organ which can be subcultured for a long time, so that the problems of difficult acquisition of placenta samples and ethics limitation in the clinical early stage are reduced. Meanwhile, L-NAME is used for performing drug-induced injury, a trophoblast organ injury model for simulating the placental pathological state of preeclampsia can be constructed, and compared with traditional hypoxia-induced injury, the method is more convenient, and the limitation of instruments and equipment is reduced.

This invention belongs to the medical field and provides a human trophoblastic stem cell line derived from complete hydatidiform mole and its applications. The human trophoblastic stem cell line, with accession number CGMCC No. C2024411, can be induced to differentiate into syncytiotrophoblast and extravillous trophoblast, mimicking the differentiation and developmental defects of the trophoblastic lineage in hydatidiform mole. It can be used as an in vitro research model for complete hydatidiform mole and has broad application prospects in drug target research and genetic studies.

The invention relates to a method for detecting early embryo death of cattle and sheep, which is characterized by comprising the following steps of: 1) determining the detection time of early embryo death: when oestrus behavior characteristics of cows and ewes are observed by a pedometer or naked eyes, determining the time as the detection time; 2) detecting early embryo death: taking 5-10ml of cow and ewe blood, standing for 1-2 hours in a shade place, separating serum, respectively inserting bovine trophoderm protein-1 detection test paper and sheep trophoderm protein-1 detection test paper into the cow and ewe serum for 5-10 minutes, observing the detection test paper 15-18 minutes after the detection test paper is taken out, and when the detection test paper develops color, detecting the early embryo death; the cows or ewes are successfully fertilized and form early embryos, but still have estrus behavior characteristics, and the embryos are proved to be dead. Whether embryos die or not can be detected in time, the problems that the feeding cost is increased in the non-pregnant period, the number of fertilization opportunities caused by blind mating is small, and wombs of cattle and sheep are injured are solved, and by reasonably waiting for mating, the breeding efficiency is greatly improved, the yield of milk and goat milk is increased, and the income of a feeding farm is increased.

The present disclosure relates to antigen-binding molecules that bind to human and feline Human Trophoblast Cell Surface Antigen 2 (TROP2). The specific embodiments relate to antibody-drug conjugates (ADC) comprising saporin, mertansine and MMAE and chimeric antigen receptors (CAR) comprising said antigen-binding molecules for use in treatment of cancer.

The invention discloses a line establishment method and a culture system of bovine trophoblast stem cells. The stem cell line is obtained by separation and induction from bovine blastocyst. The embryonic stem cell line has stability. The method can be applied to various life science and medical fields such as bovine animal breeding and breeding, gene editing models, animal cloned donor cells, medical musculoskeletal injury experiments, drug development carriers, vaccine production cell banks, embryo quality analysis and the like, and can be applied to large-scale production and application.

The application relates to the field of biotechnology, in particular to application of CADM1 in preparation of a drug for gestational diabetes mellitus. The application comprises: using a detection reagent for detecting the expression level of CADM1 in preparation of a detection drug for gestational diabetes mellitus. The application is based on the previous research of the applicant that the expression level of CADM1 in the placental trophoblast of a gestational diabetes mellitus patient is reduced, and it is found in an in-vitro experiment that CADM1 can promote the proliferation, migration and invasion of the placental trophoblast cells, and by constructing an mRNA expression amount of CADM1 and a receiver operating characteristic curve of a subject of a GDM patient, it is indicated that the mRNA expression amount of CADM1 is related to the GDM patient, which indicates that CADM1 is related to the placental trophoblast of the gestational diabetes mellitus patient, and it is indicated that the detection of the gestational diabetes mellitus can be realized by detecting the detection reagent for detecting the expression level of CADM1.

The application provides a trophoblast organ-on-chip system for simulating a maternal-fetal interface of a systemic lupus erythematosus model based on an organ chip and a construction method thereof, the system taking an organ chip as a carrier and comprising three core parts of a trophoblast organ, an endometrial chip and an SLE disease model. The application completes separation culture and characterization of the trophoblast organ, multi-cell co-culture construction and characterization of the endometrial chip, and then constructs a pathological model, and the three parts cooperatively form a three-dimensional maternal-fetal interface. The system can clearly observe the dynamic process of the trophoblast organ invading the endometrial chip, can detect the continuous secretion of hCG and SLE-related inflammatory factors, and breaks through the defects of the prior art model, such as low authenticity, inability to dynamically observe, single detection dimension and lack of standardization, and has both physiological and pathological adhesion and experimental repeatability, can multi-dimensionally characterize the cell phenotype and function of the maternal-fetal interface, and provides an in-vitro research platform for the pathological mechanism research of the SLE pregnancy-related abnormal maternal-fetal interface.

The invention discloses application of a series of extremely early stem cells or differentiated cell lineages thereof in preparation and detection of influenza viruses and drug screening, and belongs to the field of cell application. Specifically, trophoblast stem cells (TSC) and amnion-like stem cells (AME) obtained by extremely early cell induced differentiation and screening are used for influenza virus infection or screening test. Experiments prove that extraembryonic differentiation cell models such as trophoblast stem cells, amniotic stem cells and / or differentiated cell lineages thereof are highly susceptible to influenza viruses, and have important application values in the aspects of efficient preparation and detection of viruses and variants thereof, preparation of preventive vaccines and screening of therapeutic drugs. The method not only aims at human-derived influenza viruses and variants thereof, but also has important significance on prevention and treatment of animal influenza and variants thereof.

The invention belongs to the technical field of medical diagnosis, and provides a biomarker of complete grape tire. The biomarker comprises RASA1, and the biomarker shows obvious differential expression in normal and complete grape tire trophoblast stem cells and normal and complete grape tire tissues; the method can be used for distinguishing complete grape tire, extremely early complete grape tire, non-grape tire villus edema and normal placenta tissue, and shows good robustness. Compared with the serum beta-hCG level, the expression level of the RASA1 shows higher diagnostic efficacy on complete grape tire detection. The biomarker disclosed by the invention provides a basis for developing targeted diagnosis and treatment in the future.

The invention discloses an application of miR-146b-3p inhibitor in improving sheep embryo implantation abnormity caused by LPS (Lipopolysaccharide), and belongs to the technical field of biology, and the sequence of the miR-146b-3p inhibitor is shown as SEQ ID No.1. The invention further discloses a preparation method of the miR-146b-3p inhibitor. LPS can cause sheep endometrial epithelial cell inflammatory factor abnormity, adhesion molecule expression change, trophoblast sphere adhesion growth inhibition and miR-146b-3p expression increase, miR-146b-3p inhibits GYS2 gene expression in a targeted manner, endometrial glycogen synthesis is reduced, and embryo implantation is affected. The miR-146b-3p inhibitor can be used for rescuing GYS2 expression reduction caused by LPS (Lipopolysaccharide), relieving glycogen synthesis reduction and expression inhibition of an attachment key gene, promoting sheep embryo attachment and reducing the embryo loss rate. The invention further provides a reagent containing the inhibitor, a reagent for overexpressing the GYS2 gene, a method for promoting embryo implantation and related products, a new direction is provided for improving the reproductive performance of sheep, and the inhibitor has important value and significance for the sheep raising industry.

Antibodies and antigen-binding fragments thereof specific to Trophoblast cell surface antigen 2 (Trop2). Also provided are anti-Trop2 antibody-drug conjugates (ADCs), Trop2-specific chimeric antigen receptor, and multispecific antigen binding proteins, such as bispecific T cell engagers (BiTEs), which bind to Trop2 and other targets. Further provided are compositions comprising the anti-Trop2 antibodies and antigen-binding fragments thereof, a method of diagnosis and cancer treatment employing the anti-Trop2 antibodies and antigen-binding fragments thereof.

The invention belongs to the technical field of biological medicine, and particularly relates to application of beta cell protein in preparation of medicine for preventing and treating abortion. Research finds and verifies for the first time that application of beta cell protein (BTC) promotes invasion and tubulation processes of extravillus trophoblast cell line-HTR8 cells, BTC has an obvious rescue effect on embryo absorption in abortion model mice in early and middle stages of pregnancy, and BTC is injected into the abortion model mice in an intraperitoneal cavity in early and middle stages of pregnancy to increase placenta weight, so that the abortion model mice in early and middle stages of pregnancy have an obvious rescue effect on embryo absorption. Therefore, the BTC has a certain treatment effect on the abortion, so that the BTC has a good practical application value.

The application provides a blastocyst three-dimensional fitting reconstruction method and device, electronic equipment and storage medium. The method comprises the following steps: acquiring a plurality of focal plane images of a blastocyst; identifying a trophoblast cell mask and an inner cell mass mask in the blastocyst based on the plurality of focal plane images; constructing a trophoblast cell grid model and an inner cell mass grid model according to the trophoblast cell mask and the inner cell mass mask; constructing a depth map of the blastocyst according to the plurality of focal plane images; performing image fusion on the plurality of focal plane images to obtain a texture image; performing plane mapping according to the texture image and the depth map to generate an internal three-dimensional point cloud model of the blastocyst; constructing a three-dimensional geometric model of the blastocyst according to the trophoblast cell grid model, the inner cell mass grid model and the internal three-dimensional point cloud model; and mapping the texture image to the surface of the three-dimensional geometric model to generate a blastocyst three-dimensional model. The reconstruction based on the method does not affect the development of the embryo, and is low in cost and safe and reliable.

The separation and detection method comprises the following steps: rinsing placenta or villus tissues in a PBS (Phosphate Buffer Solution) added with a 1% penicillin-streptomycin double antibody solution, digesting the placenta or villus tissues into single cells by using a 1640 culture medium containing I-type and IV-type collagenase after the placenta or villus tissues are rinsed sufficiently to obtain a cell suspension, and culturing the cell suspension for later use; diluting and neutralizing collagenase digestive juice by using a 1640 culture medium containing high-temperature heat-inactivated fetal calf serum according to 5 times of volume; repeatedly discarding the precipitate, recovering the supernatant, and centrifuging to obtain a coarse migration body; and establishing a density gradient by using Optiprep as a density medium, washing the precipitate with PBS, and centrifuging to obtain the trophoblast cell-derived transporter. The invention provides a group of placenta villus trophoblast cell source migration body specific expression membrane proteins for the first time, and provides a method for specifically capturing the placenta trophoblast source migration body on the basis of the placenta villus trophoblast cell source migration body specific expression membrane proteins, so that a new direction for researching a trophoblast dysfunction related disease mechanism can be enriched.

The invention provides an NK cell in-vitro efficient culture system and application, the culture system comprises a K562 engineering cell, and six proteins of IL21, IL12, IL15, CD40L, CD155 and CD112 are expressed on a cell membrane of the K562 engineering cell in a transmembrane mode; the NK cell culture composition comprises the following components: a liquid serum-free cell culture medium, 1-5% (v / v) of autologous plasma, 100-250 [mu] g / ml of an astragalus extract and 200-500 [mu] g / ml of an angelica sinensis extract, and the dosage ratio of the astragalus extract to the angelica sinensis extract is 1: 2. The NK cell with high amplification multiple, high purity and high lethality can be obtained by a culture system established by taking the K562 engineering cell constructed by the invention as a trophoblast cell, taking an astragalus extract and an angelica sinensis extract as culture additives and taking PBMC as an original culture material, and the culture system has important significance for treating cancers by cell drugs.

The invention discloses a culture medium for goat trophoblast organoid, a culture method and application, and belongs to the field of goat trophoblast organoid culture. The method comprises the following steps: separating trophoblast tissues from a healthy goat placenta which is pregnant for 80-90 days, digesting the trophoblast tissues through type II collagenase to obtain primary cells, compounding the primary cells with matrigel, and performing three-dimensional culture in an improved trophoblast organ culture medium with specific components to form mature organs. The organ is of a typical three-dimensional structure, and KRT23 and SOX2 markers are stably expressed. The organoid culture system based on the goat primary trophoblast cells is established for the first time, gene modification is not needed, the in-vivo physiological status is highly simulated, and the culture system is standardized and good in repeatability. The constructed organoid can be used as an ideal in-vitro model for researching placenta development, evaluating drugs and toxins and modeling infectious diseases in the gestation period, and is of great significance in improving the reproductive research level of goats and the production benefits of animal husbandry.

The invention is applicable to the technical field of biological medicines, provides application of ophiopogon japonicus borneol glycoside in preparation of a medicine for preventing and treating gestational metabolic diseases, and aims to solve the technical problems that the conventional medicine is limited in use during pregnancy, and the curative effect and the safety are difficult to take into account. According to verification of multi-model systems such as animals, cells and human-derived trophoblast organs, it is found that ophiopogon japonicus borneol glycoside can significantly improve gestational glycometabolism disorder, improve insulin sensitivity and reduce insulin resistance, and therefore effective intervention on gestational diabetes mellitus is achieved. As a natural component derived from the Zhejiang radix ophiopogonis, the radix ophiopogonis borneol glycoside has definite pharmacological activity and excellent safety, and the Zhejiang radix ophiopogonis is listed in a national homology of medicine and food, so that reliable safety guarantee is provided for use during pregnancy.

The invention belongs to the field of medicine, and provides a complete grape embryo-derived human trophoblast stem cell line and application thereof. The preservation number of the human trophoblast stem cell line is CGMCC No.C2024411, and the human trophoblast stem cell line can be induced and differentiated into a syncytial trophoblast and an extravillus trophoblast, can simulate differentiation and development defects of a grape embryo trophoblast pedigree, can be applied as an in-vitro research model of a complete grape embryo, and has a wide application prospect in drug target research and genetic research.

The application discloses a preeclampsia diagnosis and treatment biological marker and application thereof; the application deeply demonstrates the mechanism that high expression DHRS4 causes PE by inhibiting the invasiveness of trophoblasts from the clinical sample, cells and in vivo level, and overexpression DHRS4 in the application combines and up-regulates LONP2, degrades TFAM protein through ubiquitination, causes mitochondrial dysfunction, weakens the migration and invasion ability of trophoblasts, participates in the mechanism of PE occurrence, is a new mechanism clue obtained according to the pre-experiment results and information analysis, is a new target for deeply exploring the clinical diagnosis and treatment of PE, and the research result can provide a theoretical basis for guiding the early prediction and intervention of PE in the future.

FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex

The invention relates to the technical field of biological information processing, in particular to a cattle embryo pre-implantation genetic evaluation method and system based on whole genome sequencing, and the method comprises the following steps: obtaining whole genome sequencing data of a male parent and a female parent, embryo trophoblast live detection sequencing data and culture solution free desoxyribonucleic acid sequencing data; performing variation detection and haplotype phasing on male and female parent data to form haplotype data, and calculating a haplotype transmission posterior at an anchor point based on trophoblast data; performing genome segmentation based on reading depth observation and allele frequency observation of a trophoblast and a culture solution, and performing Bayesian inference by combining haplotype transfer posteriori as priori to obtain posteriori probabilities of aneuploid, copy number variation, chimera, pathogenic homozygosis and pollution events; and outputting a passing / rechecking / elimination conclusion, adding sequencing and updating the posteriori during rechecking until ending, and outputting a final conclusion and a genome breeding value, so that the evaluation reliability and the decision interpretability are improved.

The invention relates to the field of cell genetic engineering, and discloses a high-sensitivity embryo chromatin analysis method which comprises the following steps: S1, puncturing an embryo zona pellucida through a micromanipulation instrument, sucking 5-8 trophoblast cells, and immersing a sample into 4 DEG C chromatin stabilizing liquid containing 1mM of ethylenediamine tetraacetic acid and bovine serum albumin within 8 seconds after the sample is obtained; s2, processing the sample by adopting a gradient fixation method; s3, sequentially carrying out low-intensity ultrasonication and restriction enzyme combined treatment; s4, carrying out specific labeling by using a double-labeling probe system; s5, implementing two-stage signal amplification in the micro-fluidic chip; and S6, carrying out three-dimensional space conformation analysis by adopting a super-resolution microscope. A silicon nitride microscopic needle penetrates through the zona pellucida at a puncture angle of 75-85 degrees, and the suction speed is controlled to be 0.5 mu L / s in combination with a PID closed loop, so that the DNA fragmentation rate can be reduced to 2.1 + / -0.3% (the proportion of 5kb fragments is 98.5%), and the embryo survival rate is gt; the H3K9 acetylation modification level is improved by 5.3 times, and the chromatin accessibility is improved.

The invention provides application of a reagent for detecting KAT5 or H2A.Zac in preparation of a product for diagnosing placenta-derived diseases, and relates to the technical field of biomedicine. Experimental research of the inventor finds that chromosomes of trophoblasts in placentas of patients with repeated pregnancy loss are unstable, and expression of KAT5 and H2A.Zac is remarkably reduced. Experiments prove that KAT5-mediated H2A. Zac reduction is a main reason for reduction of trophoblast chromosome stability, so that the KAT5-H2A. Zac pathway provides a new action target for diagnosis and treatment of placenta-derived diseases, diagnosis and / or treatment of placenta-derived diseases can be realized, a new treatment strategy is provided for clinical improvement of poor pregnancy outcome, and the application of the KAT5-H2A. Zac pathway in diagnosis and treatment of placenta-derived diseases is developed. Therefore, the health level of female fertility can be improved, and gestation complications such as abortion and fetal growth limitation can be reduced.